Edgewise Therapeutics, Inc. (EWTX)
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Edgewise Therapeutics, Inc.
NASDAQ:EWTXHealthcare · Biotechnology
-0.03%$38.90
AH$39.10+0.51%vs close
Mkt Cap$4.22B
Float70.49M
O/S108.6M
Vol
$ Vol
RVOL
Inst Own-
SI16.7%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$167.79M
Total Assets$552.6M
Free Cash Flow-$143.82M
Debt & Equity
Debt 1%
Equity 99%
Total Debt$3.99M
Total Equity$522.26M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in EWTX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$552.6M
Liabilities$30.35M
Accounts Receivable$0
Accounts Payable$6.01M
Inventory$0
PP&E (Net)$9.22M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - |
| Cost of Revenue | $2.27M | $0 | $0 | $0 | $0 | $185K | $123K |
| Gross Profit | -$2.27M | $0 | $0 | $0 | $0 | -$185K | -$123K |
| Gross Margin | - | - | - | - | - | - | - |
| Research and Development | $151.39M | $126.97M | $90.91M | $54.03M | $32.19M | $14.8M | $8.62M |
| Selling, General, and Administrative | $40.02M | $31.87M | $23.45M | $17.63M | $11.03M | $2.21M | $1.3M |
| Other | -$2.27M | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $189.14M | $158.83M | $114.36M | $71.66M | $43.22M | $17.01M | $9.92M |
| Operating Income (EBIT) | -$191.41M | -$158.83M | -$114.36M | -$71.66M | -$43.22M | -$17.19M | -$9.92M |
| Operating Margin | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $4.02M | $0 | $0 | $0 |
| Interest Income | $23.61M | $25.02M | $14.19M | $2.66M | $402K | $69K | $219K |
| Other Income (Expense) | $23.61M | $25.02M | $14.19M | $4.02M | $402K | $69K | $219K |
| Income Before Tax (EBT) | -$167.79M | -$133.81M | -$100.16M | -$67.64M | -$42.81M | -$17.12M | -$9.71M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$167.79M | -$133.81M | -$100.16M | -$67.64M | -$42.81M | -$17.05M | -$9.49M |
| Net Income Margin | - | - | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -1.63 | -1.45 | -1.57 | -1.26 | -0.86 | -0.35 | -0.19 |
| Diluted EPS | -1.63 | -1.45 | -1.57 | -1.26 | -0.86 | -0.35 | -0.19 |
| Weighted Average OS | 102.93M | 92.41M | 63.72M | 53.59M | 49.50M | 49.22M | 49.22M |
| EBITDA | -$165.53M | -$131.52M | -$98.43M | -$63.08M | -$42.54M | -$17.01M | -$9.8M |
| EBITDA Margin | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $61.15M | $41.67M | $86.1M | $21.99M | $15.57M | $104.92M | $23.65M |
| Short-Term Investments | $468.96M | $428.5M | $232.3M | $329.95M | $265.22M | $24.18M | $0 |
| Cash and Short-Term Investments | $530.11M | $470.17M | $318.39M | $351.95M | $280.79M | $129.09M | $23.65M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $13.28M | $5.31M | $8.6M | $0 | $0 | $0 | $0 |
| Total Current Assets | $543.38M | $475.48M | $327M | $357M | $283.77M | $129.65M | $24.04M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $9.22M | $11.07M | $12.69M | $9.85M | $912K | $516K | $498K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $262K | $348K | $251K | $548K | $975K | $0 |
| Total Long-Term Assets | $9.22M | $11.33M | $13.04M | $10.1M | $1.46M | $1.49M | $498K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $552.6M | $486.82M | $340.04M | $367.1M | $285.23M | $131.14M | $24.54M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $6.01M | $5.58M | $4.03M | $6.11M | $3.84M | $1.58M | $667K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $12.43M | $10.06M | $5.7M | $4.03M | $2.8M | $452K | $333K |
| Total Current Liabilities | $27.37M | $23.86M | $16.77M | $16.59M | $10.52M | $4.34M | $1.13M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $2.98M | $0 | $0 | $0 | $0 | $160.21M | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $329K | $0 | $40.26M |
| Total Long-Term Liabilities | $2.98M | $3.74M | $4.43M | $3.8M | $329K | $160.21M | $40.26M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $30.35M | $27.6M | $21.2M | $20.39M | $10.85M | $164.56M | $41.39M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $10K | $9K | $7K | $6K | $5K | $0 | $0 |
| Retained Earnings | -$546.37M | -$378.58M | -$244.76M | -$144.6M | -$76.96M | -$34.15M | -$17.02M |
| Comprehensive Income & Other | $677K | $420K | $99K | -$1.35M | -$514K | $0 | $0 |
| Other Stockholders' Equity | $1.07B | $837.78M | $563.59M | $491.31M | $351.34M | $727K | $171K |
| Total Equity | $522.26M | $459.22M | $318.83M | $346.72M | $274.38M | -$33.42M | -$16.85M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $552.6M | $486.82M | $340.04M | $367.1M | $285.23M | $131.14M | $24.54M |
| Supplementary Data | |||||||
| Total Debt | $3.99M | $4.74M | $5.41M | $4.41M | $0 | $160.21M | $0 |
| Net Debt | -$57.16M | -$36.93M | -$80.68M | -$17.59M | -$15.57M | $55.3M | -$23.65M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$167.79M | -$133.81M | -$100.16M | -$67.64M | -$42.81M | -$17.12M | -$9.71M |
| Depreciation & Amortization | $2.27M | $2.29M | $1.73M | $538K | $272K | $185K | $123K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | -$2.29M | $0 | $0 |
| Stock-Based Compensation | $34.75M | $24.71M | $17.56M | $10.92M | $4.4M | $354K | $77K |
| Changes in Working Capital: | |||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $272K | $1.74M | -$92K | $47K | $2.65M | $521K | $275K |
| Other Working Capital | -$5.65M | $8.59M | -$1.47M | $4.04M | $1.98M | $1.43M | $59K |
| Total Working Capital Change | -$5.37M | $10.33M | -$1.56M | $4.09M | $4.63M | $1.95M | $334K |
| Other Non-Cash Items | -$7.67M | -$12.54M | -$9.52M | -$543K | $2.29M | $0 | $0 |
| Net Cash from Operating | -$143.82M | -$109.03M | -$91.95M | -$52.63M | -$33.51M | -$14.63M | -$9.17M |
| Investing Activities | |||||||
| Capital Expenditures | -$256K | -$1.31M | -$5.75M | -$5.55M | -$668K | -$203K | -$180K |
| Acquisitions | $0 | $0 | $0 | $65K | $242K | $0 | $0 |
| Purchases of Investments | -$527.23M | -$477.06M | -$255.87M | -$292.39M | -$288.2M | -$24.18M | $0 |
| Sales of Investments | $494.69M | $293.71M | $364.5M | $227.36M | $46.64M | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | -$65K | -$242K | $0 | $0 |
| Net Cash from Investing | -$32.79M | -$184.66M | $102.89M | -$70.58M | -$242.23M | -$24.38M | -$180K |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | - | - | - |
| Common Stock Issuance | $196.09M | $239.15M | $52.62M | $129.16M | $186.15M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $10.11M | $548K | $474K | $236K | $202K | $22K |
| Net Cash from Financing | $196.09M | $249.25M | $53.17M | $129.64M | $186.38M | $120.28M | $24.8M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $19.48M | -$44.43M | $64.1M | $6.43M | -$89.35M | $81.26M | $15.45M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$143.82M | -$109.03M | -$91.95M | -$52.63M | -$33.51M | -$14.63M | -$9.17M |
| Capital Expenditure | -$256K | -$1.31M | -$5.75M | -$5.55M | -$668K | -$203K | -$180K |
| Free Cash Flow | -$143.82M | -$110.34M | -$97.69M | -$58.18M | -$34.17M | -$14.84M | -$9.35M |
| Cash at Beginning | $41.67M | $86.1M | $21.99M | $15.57M | $104.92M | $23.65M | $8.2M |
| Cash at End | $61.15M | $41.67M | $86.1M | $21.99M | $15.57M | $104.92M | $23.65M |